U.S. patent application number 10/033169 was filed with the patent office on 2003-07-24 for methods for improving the aesthetic appearance of skin.
This patent application is currently assigned to AVON PRODUCTS, INC.. Invention is credited to Ptchelintsev, Dmitri.
Application Number | 20030138467 10/033169 |
Document ID | / |
Family ID | 21868908 |
Filed Date | 2003-07-24 |
United States Patent
Application |
20030138467 |
Kind Code |
A1 |
Ptchelintsev, Dmitri |
July 24, 2003 |
Methods for improving the aesthetic appearance of skin
Abstract
There are provided methods and compositions for improving the
aesthetic appearance of akin, treating rosacea and/or
telangiectasia, and treating the signs of dermatological aging. The
method is directed to topically applying to an affected area an
effective amount of mangostin, an analog thereof, or a combination
thereof.
Inventors: |
Ptchelintsev, Dmitri;
(Jersey City, NJ) |
Correspondence
Address: |
Charles N.J. Ruggiero, Esq.
Ohlandt, Greeley, Ruggiero & Perle, L.L.P.
10th Floor
One Landmark Square
Stamford
CT
06901-2682
US
|
Assignee: |
AVON PRODUCTS, INC.
NEW YORK
NY
|
Family ID: |
21868908 |
Appl. No.: |
10/033169 |
Filed: |
December 27, 2001 |
Current U.S.
Class: |
424/401 ; 514/27;
514/455 |
Current CPC
Class: |
A61Q 19/02 20130101;
A61P 29/00 20180101; A61P 17/00 20180101; A61P 17/02 20180101; A61P
17/16 20180101; A61P 39/06 20180101; A61Q 19/08 20130101; A61K
8/498 20130101; A61P 37/08 20180101; A61P 17/04 20180101 |
Class at
Publication: |
424/401 ; 514/27;
514/455 |
International
Class: |
A61K 031/7048; A61K
007/00; A61K 031/353 |
Claims
What is claimed is
1. A composition for treating skin comprising: an ingredient
represented by the following formula: 2wherein R.sub.1, R.sub.2,
R.sub.3 and R.sub.4 may, independently, be a hydrogen atom; a
carbohydrate; an acyl group, substituted or unsubstituted,
straight-chain or branched, fully saturated or having one or more
unsaturated bonds, and have from 1 to 22 carbon atoms; an alkyl
group, substituted or unsubstituted, straight-chain or branched,
fully saturated or having one or more unsaturated bonds, and have
from 1 to 22 carbon atoms; an alkenyl group, substituted or
unsubstituted, straight-chain or branched, fully saturated or
having one or more unsaturated bonds, and have from 1 to 22 carbon
atoms; an alkynyl group, substituted or unsubstituted,
straight-chain or branched, fully saturated or having one or more
unsaturated bonds, and have from 1 to 22 carbon atoms; a phenyl
group, substituted or unsubstituted; a benzyl group, substituted or
unsubstituted; a cycloalkyl group, substituted or unsubstituted,
and have from 3 to 8 carbon atoms; a cycloalkenyl group,
substituted or unsubstituted, and have from 4 to 8 carbon atoms;
and an oxaalkyl, oxaalkenyl, or oxaalkynyl group having at least
one oxygen atom in its backbone structure, substituted or
unsubstituted, and straight-chained or branched; and a cosmetically
acceptable vehicle.
2. The composition of claim 1, wherein at least two of R.sub.1,
R.sub.2, R.sub.3 and R.sub.4 are hydrogen atoms.
3. The composition of claim 1, wherein R.sub.1 is an alkyl group or
an acyl group having from 1 to 12 carbon atoms, and wherein
R.sub.2, R.sub.3 and R.sub.4 are each hydrogen atoms.
4. The composition of claim 1, wherein the composition is in a
product form selected from the group consisting of aerosol spray,
cream, dispersion, foam, gel, lotion, mask, mousse, ointment,
powder, patch, pomade, solution, pump spray, stick, tape, and
towelette.
5. The composition of claim 1, wherein the ingredient is present in
an amount about 0.0001 w % to less than 100 wt % based on the total
weight of the composition.
6. The composition of claim 1, wherein the ingredient is present in
an amount about 0.0001 w % to about 90 wt % based on the total
weight of the composition.
7. The composition of claim 1, wherein the ingredient is present in
an amount about 0.01 w % to about 50 wt % based on the total weight
of the composition.
8. The composition of claim 1, wherein the ingredient is present in
an amount about 0.5 w % to about 20 wt % based on the total weight
of the composition.
9. The composition of claim 1, wherein the ingredient is
1,3,6-trihydroxy-7-methoxy-2,8-di(3-methyl-2-butenyl)xanthone.
10. A method for treating a skin condition selected from the group
consisting of rosacea, telangiectasia, dermatological signs of
aging and any combination thereof, the method comprising topically
applying to an affected area an effective amount of the composition
of claim 1.
11. The method of claim 10, wherein the skin condition is
rosacea.
12. The method of claim 10, wherein the skin condition is
telangiectasia.
13. The method of claim 12, wherein the telangiectasia includes the
appearance of spider veins, broken capillaries or if both.
14. The method of claim 10, wherein the skin condition is the
dermatological signs of aging.
15. The method of claim 14, wherein the dermatological signs of
aging includes at least one of skin fragility; loss of collagen
and/or elastin; skin atrophy; appearance and/or depth of lines
and/or wrinkles; fine lines; skin discoloration; skin fatigue
and/or stress; loss of skin tone, clarity or luster; loss of skin
firmness; poor skin texture; loss of skin elasticity and/or
resiliency; and thin skin.
16. The method of claim 10, wherein the composition is applied for
an effective period of time.
17. The method of claim 10, wherein the composition is applied
daily for about 1 week.
18. The method of claim 10, wherein the composition is applied
daily for about 2 weeks.
19. A method for improving the aesthetic appearance of skin, the
method comprising topically applying to the skin an effective
amount of the composition of claim 1.
20. The method of claim 19, wherein the composition is applied for
an effective period of time.
21. The method of claim 19, wherein the composition is applied
daily for about 2 weeks.
22. The method of claim 19, wherein the ingredient is present in an
amount about 0.01 w % to about 50 wt % based upon the total weight
of the composition.
23. The method of claim 19, wherein the ingredient is
1,3,6-trihydroxy-7-methoxy-2,8-di (3-methyl-2-butenyl)
xanthone.
24. A method for treating sensitive skin, the method comprising
topically applying to an affected area of the skin an effective
amount of the composition of claim 1.
25. The method of claim 24, wherein the composition is applied for
an effective period of time.
26. The method of claim 24, wherein the composition is applied
daily for about 2 weeks.
27. The method of claim 24, wherein the ingredient is present in an
amount about 0.01 w % to about 50 wt % based on the total weight of
the composition.
28. The method of claim 19, wherein the ingredient is
1,3,6-trihydroxy-7-methoxy-2,8-di (3-methyl-2-butenyl)
xanthone.
29. A method for treating at least one skin condition selected from
the group consisting of itch, irritation, inflammation, loss of
tone, redness, allergic responses, combination skin, blemishes,
flushing and blushing, the method comprising topically applying to
an affected area of the skin an effective amount of the composition
of claim 1.
30. The method of claim 29, wherein the composition is applied for
an effective period of time.
31. The method of claim 29, wherein the composition is applied
daily for about 2 weeks.
32. The method of claim 29, wherein the ingredient is present in an
amount about 0.01 w % to about 50 wt % based on the total weight of
the composition.
33. The method of claim 29, wherein the ingredient is
1,3,6-trihydroxy-7-methoxy-2,8-di (3-methyl-2-butenyl) xanthone.
Description
BACKGROUND OF THE INVENTION
[0001] 1. Field of the Invention
[0002] The present invention relates to methods for improving the
aesthetic appearance of skin. The present invention further relates
to methods of treating sensitive skin, methods of treating rosacea
and/or telangiectasia, and methods of treating dermatological signs
of aging. The present invention further relates the topical
application of an effective amount of mangostin or an analog
thereof.
[0003] 2. Description of the Prior Art
[0004] Cosmetic products, which enhance the appearance of skin, are
increasingly in demand. Consumers are interested in mitigating or
delaying the signs of chronologically or hormonally aged or
photo-aged skin, such as fine lines, wrinkles, drying, and sagging
skin. During the aging process, the complexion of the skin, i.e.,
the color and appearance of the skin, deteriorates slowly from
aging and/or exposure to sunlight.
[0005] Numerous cosmetic and medical treatments have been developed
in an attempt to treat aged skin, as well as sensitive skin,
rosacea, telangiectasia and related conditions. Rosacea and its
clinical manifestations are known by those in the art. A
description of rosacea and related literature is set forth in U.S.
Pat. No. 5,972,993 at col. 1, line 15 through col. 2, line 55,
which is incorporated herein by reference.
[0006] Telangiectasia typically presents as superficial cutaneous
capillaries near the surface of the skin having a bright red center
portion and branching radiations. Such a skin condition is often
called "spider veins." When telangiectasia includes capillaries
that are burst, leak blood or other fluids and/or become highly
branched, the skin condition is commonly referred to as "broken
capillaries." Telangiectasia may be spurred by UV exposure, stress,
environmental conditions, injury and/or general skin aging.
[0007] The prior art discloses treatments for telangiectasia. U.S.
Pat. No. 5,268,176 provides for treatment via repeated applications
of a composition having inositol phosphoric acid or derivatives
thereof. U.S. Pat. No. 5,698,206 provides for treatment via topical
application of natural herbs in a carrier oil and concurrent
ingestion of vitamin C.
[0008] Persons having rosacea and/or telangiectasia frequently
address the skin irregularities brought on by those conditions by
the application of cosmetics to mask the appearance of the skin.
While the use of cosmetics is not deleterious to the health of the
person, they do not mitigate or ameliorate the underlying
conditions.
[0009] Mangostin has been employed in the prior art for a variety
of purposes, but heretofore has not been employed to treat rosacea,
telangiectasia, or aging skin. French Patent No. 2,754,447 relates
to sunscreen compositions having mangostin. Japanese Patent
Publication No. 10072357 relates to antiallergenic agents and foods
having mangostin. The publication, Antimicrobial Activities of
Chemical Constituents from Garcinia mangostana, J. Sci. Soc.
Thailand (1986), 12(4), pages 239-43, relates to the use of
mangostin and mangostin derivatives as antimicrobials. The
publication, The Structure of Garcinone E, Chem. Pharm. Bull.
(1993), 41(5), pages 958-60, relates to the use of mangostin
analogs as anti-tumor agents.
[0010] It would be desirable to have a topical composition to
improve the aesthetic appearance of the skin. It would also be
desirable to have an effective treatment for sensitive skin. It
would also be desirable to have an effective treatment for rosacea
and/or telangiectasia. It would also be desirable to have an
effective treatment for the dermatological signs of aging.
SUMMARY OF THE INVENTION
[0011] It is an object of the present invention to provide a method
for improving the aesthetic appearance of skin.
[0012] It is another object of the present invention to provide a
method for treating sensitive skin.
[0013] It is also an object of the present invention to provide a
method for treating rosacea.
[0014] It is also an object of the present invention to provide a
method for treating telangiectasia.
[0015] It is still another object of the present invention to
provide a method for treating the signs of dermatological
aging.
[0016] These and other objects and advantages of the present
invention are achieved by a method of topically applying to an
affected area an effective amount of mangostin and/or an analog
thereof.
[0017] These and other objects of the invention are also achieved
by a method of topically applying to an affected area an effective
amount of a natural extract of mangostin and/or an analog
thereof.
DETAILED DESCRIPTION OF THE INVENTION
[0018] It was found surprising that there are methods for improving
the appearance of skin, treating sensitive skin, treating rosacea
and/or telangiectasia, and treating the signs of dermatological
aging, particularly with respect to the face, legs and/or torso. It
was also surprisingly found that such methods are effected by
topically applying to the affected area an effective amount of
mangostin or an analog thereof.
[0019] The terms "treating" or "treat" as used in the present
invention mean reduce, diminish, ameliorate, or prevent. To improve
skin appearance means to partially or fully restore the normal
appearance of the skin.
[0020] Mangostin and its analogs are compounds that can be derived
from natural sources (e.g., Garcinia mangostana L., Guttiferae as
described in Schmid, Ann. 93, 83 (1855)) and/or synthesized.
[0021] Mangostin and its analogs can be represented by the
following general formula: 1
[0022] wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 may,
independently, be any of the following: a hydrogen atom; a
carbohydrate; an acyl group, substituted or unsubstituted,
straight-chain or branched, fully saturated or having one or more
unsaturated bonds, that has from 1 to 22, preferably 1 to 18, and
most preferably from 1 to 12, carbon atoms; an alkyl group,
substituted or unsubstituted, straight-chain or branched, fully
saturated or having one or more unsaturated bonds, that has from 1
to 22, preferably 1 to 18, and most preferably from 1 to 12, carbon
atoms; an alkenyl group, substituted or unsubstituted,
straight-chain or branched, fully saturated or having one or more
unsaturated bonds, that has from 1 to 22, preferably from 1 to 18,
and most preferably from 1 to 12 carbon atoms; an alkynyl group,
substituted or unsubstituted, straight-chain or branched, fully
saturated or having one or more unsaturated bonds, that has from 1
to 22, preferably 1 to 18, and most preferably from 1 to 12, carbon
atoms; a phenyl group, substituted or unsubstituted; a benzyl
group, substituted or unsubstituted; a cycloalkyl group,
substituted or unsubstituted, that has from 3 to 8, preferably from
4 to 7, and most preferably from 5 to 6, carbon atoms; a
cycloalkenyl group, substituted or unsubstituted, that has from 4
to 8, preferably from 4 to 7, and most preferably from 5 to 6,
carbon atoms; and an oxaalkyl, oxaalkenyl, or oxaalkynyl group
having at least one oxygen atom in its backbone structure,
substituted or unsubstituted, and straight-chained or branched.
Suitable carbohydrates include but are not limited to glucose,
lactose, fructose, rhamnose, trehalose, or fucose. Glucose and
fucose are preferred carbohydrates. Preferably, at least two of
R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are hydrogen atoms. Most
preferably, R.sub.1 is an alkyl group or acyl group having from 1
to 12 carbon atoms and R.sub.2, R.sub.3 and R.sub.4 are each
hydrogen atoms.
[0023] Mangostin has the chemical name of
1,3,6-trihydroxy-7-methoxy-2,8-d- i(3-methyl-2-butenyl)xanthone or,
alternately, 1,3,6-trihydroxy-7-methoxy--
2,9-bis(3-methyl-2-butenyl)-9H-xanthen-9-one. The physical
properties of mangostin are set forth in The Merck Index, 10.sup.th
Edition (1983), page 818, which is incorporated herein by
reference.
[0024] Analogs of mangostin can be derived from plant or natural
sources or be prepared via conventional organic synthesis is
procedures such catalytic esterification, ethoxylation, and
etherification. Such analogs include the following: alpha
mangostin, beta mangostin, bicyclomangostin, gamma mangostin,
3-O-methylmangostin, mangostin triacetate, and
mangostin-3,6-di-O-glucoside.
[0025] In the present method, mangostin and/or its analogs can be
topically applied without a vehicle, i.e. in an amount 100 percent
by weight (wt %). More preferably, mangostin and/or its analogs are
admixed with a vehicle suitable to form a composition for topical
application. When compositions are employed, the composition
preferably has about 0.0001 wt % to less than 100 wt %, more
preferably about 0.0001 wt % to about 90 wt %, still more
preferably about 0.01 wt % to about 50 wt %, and most preferably
about 0.5 wt % to about 20 wt %, of mangostin and/or its analogs
based on the total weight of the composition.
[0026] In the present invention, mangostin and/or its analogs can
be used to improve the overall appearance of the skin and treat
sensitive skin. Treatable skin conditions include itch, irritation,
inflammation, loss of tone (e.g., sagging and/or uneven color),
redness, allergic responses, combination (oil/dry/unbalanced) skin,
blemishes, flushing and blushing.
[0027] Also in the present invention, mangostin and/or its analogs
can be used to treat dermatological signs of aging due to, for
example, chronological aging, hormonal aging and/or photoaging.
Such signs of aging include, but are not limited to, skin
fragility; loss of collagen and/or elastin; skin atrophy;
appearance and/or depth of lines and/or wrinkles including fine
lines; skin discoloration including dark eye circles; skin sagging;
skin fatigue and/or stress, e.g., skin breakout due to
environmental stress, such as pollution and/or temperature changes;
loss of skin tone, clarity or luster; loss of skin firmness; poor
skin texture; loss of skin elasticity and/or resiliency; and thin
skin.
[0028] The compositions of the present invention can be effectively
applied daily for about 1, 2 or 4 weeks, or more. Preferably, the
compositions are applied daily for about 2 weeks.
[0029] Compositions useful in the present method can be formulated
in any suitable product form. Such product forms include, but are
not limited to, aerosol spray, cream, dispersion, foam, gel,
lotion, mask, mousse, ointment, powder, patch, pomade, solution,
pump spray, stick, tape and towelette.
[0030] Compositions useful in the present method can include a
vehicle that is pharmaceutically or cosmetically acceptable. Such
vehicles include, but are not limited to, one or more C.sub.1-4
alcohols, fatty alcohols, fatty ethers, fatty esters, polyols,
glycols, vegetable oils, mineral oils, liposomes, laminar lipid
materials, silicone oils, water, or any combinations thereof.
[0031] Optionally, compositions useful in the present method can
include one or more of the following additional ingredients: amino
acids, anesthetics, anti-acne agents, anti-allergenics,
antifungals, antimicrobials, anti-inflammatory agents,
anti-irritants, antineoplastics, antioxidants, antiseptics,
antivirals, chelating agents, colorants, depigmenting agents,
emollients, emulsifiers, exfollients such as oxa acids and alpha
and beta hydroxy acids, film formers, fragrances, humectants,
hypopigmenting agents, immune system boosting agents, immune system
suppressing agents, insect repellents, lubricants, moisturizers,
pharmaceutical agents, photostabilizing agents, preservatives,
retinoids, skin protectants, skin penetration enhancers, staining
agents, sunscreens, stabilizers, surfactants, thickeners, viscosity
and/or rheology modifiers, vitamins, or any combinations
thereof.
[0032] The following are examples of the present invention.
EXAMPLE 1
[0033]
1 Oil-in-Water Emulsion wt % Humectant (e.g. Glycols, Glycerols)
0.5-15 Thickeners (e.g. Gums, Starches, Polymers) 0.1-4 Chelants
(e.g. Disodium EDTA, Tetrasodium EDTA) 0.001-0.5 Preservatives
0.01-2 Sunscreen (e.g. Parsol 1789 .TM., 0.1-50
ethylhexylmethoxycinnamate, benzophenone-3) Silicone 0.1-15 Silica
0.01-10 Extracts (e.g., one or more of 0.0001-50 Pomegranate
extract, Neem Seed Cell Broth, Grape Seed Extract, Salvia
Miltiorrhiza Extract, Iris Florentina Root Extract, Carrot Extract,
Cucumber Extract, White Birch (Betula Alba) Bark Extract, Rosemary
Extract, Algae Extract, or any combination) Fatty
alcohol/Emulsifers/Wax/Fatty acid 0.5-15 (e.g. ceteth-20
phosphate/cetearyl alcohol/ dicetyl phosphate, Tribehenin PEG-20
Ester, sodium Dihydroxycethyl phosphate, cetearyl glocoside,
cocoglyceride) Emulsion Stabilizers/Viscosity Modifiers 0.1-20
(e.g. acrylates/C.sub.10-30 alkyl acrylate crosspolymer,
acrylate/aminoacrylates/ C.sub.10-30 alkyl PEG-20 itaconate, sodium
acrylate/ acryloyldimethyl taurate copolymer, acrylates/C.sub.10-30
alkyl acrylate crosspolymer Film Formers (e.g. decene/butene
copolymer, 0.001-2 acrylates/octylacrylamide copolymer, adipic
acid/diethylene glycol/ glycerin crosspolymer) Emollients 0.1-20
Mangostin 0.5-20 Demineralized Water Q.S.
EXAMPLE 2
[0034]
2 Water/Silicone Emulsion wt % Sodium PCA 50% 0.1-4 Sodium Lactate
60% 0.01-10 Sodium Chloride 0.1-10 Humectant (Glycerin, Glycols,
Glycerols) 0.5-10 Ammonium Hydroxide 0.01-10 Cyclomethicone 0.1-20
Cyclomethicone/Dimethicone Copolyol 0.1-20 Emollients (E.G. Cetyl
Octanoate) 0.1-20 Dimethicone Copolyol/Cyclopentasiloxane 0.1-10
Alpha mangostin 0.01-50 Demineralized Water Q.S.
EXAMPLE 3
[0035]
3 Gel wt % Carbopol .TM. 0.01-3 Glycerin 0.1-30 Butylene Glycol
0.1-30 Disodium EDTA 0.01-2 Methylparaben 0.01-2 Hydroxyethyl
Cellulose 0.01-2 Corn (Zea Mays) Starch 0.01-10 C.S. D&C Yellow
No. 10 0.001-1 C.S. FD&C Blue No. 1 0.001-1 POE (20 M) Methyl
Glucose Ether 0.01-10 Dimethyl Polysiloxane 0.01-10 Peg 50 Shea
Butter 0.01-10 Sodium Hydroxide Solution 0.01-5 Benzyl Alcohol
0.01-5 Mangostin triacetate 0.001-10 Demineralized Water Q.S.
EXAMPLE 4
[0036]
4 Cleansing Foam wt % Humectant (Glycerin, Butylene Glycol) 5-25
Polyethylene Glycol 0.1-20 Bentonite 0.1-20 Stearic Acid 0.1-30
Myristic Acid 0.1-20 Cetearyl Alcohol/Ceteareth-20 1 Potassium
Hydroxide 45% 0.1-20 Preservatives (E.G. Benzyl Alcohol, 0.1-10
2-Phenoxyethanol, Benzyl Alcohol) Alpha mangostin 0.15-20
Demineralized Water Q.S.
EXAMPLE 5
[0037]
5 wt % Mixed tocopherols 1 Vitamin E succinate 1000 PEG 0.5 Gamma
Oryzanol 0.2 Lipoic Acid 0.1 Hesperetin 0.1 Naringenin 0.1 Silybin
(Silymarin) 0.1 Chlorogenic Acid 0.01 Mangostin 0.001-20 Vehicle
Q.S.
EXAMPLE 6
[0038]
6 Moisturizing Cream wt % Propyl gallate 1 Rosmantic acid 5
N-actyl-cysteine 3.5 Beta-carotene 0.001 Licorice root extract 0.01
Naringenin 2.7 PPG Myristyl Ether Propionate 6.5 Oleyl alcohol 3.5
Stearic acid 8.6 Lanolin 1 Pomegranate Extract 0.00-2 Neem Seed
Cell Broth 0.01-10 Grape Seed Extract 0.01-2 Salvia Miltiorrhiza
Extract 0.00-10 Iris Florentina Root Extract 0.00-20 Carrot Extract
0.00-2 Cucumber Extract 0.00-2 White Birch (Betula Alba) Bark
Extract 0.00-2 Rosemary Extract 0.00-2 Algae Extract 0.00-2
Glycerin 2.5 Triethanolamine 0.5 Germal 0.1 Methylparaben 0.01
Mangostin 0.001-20 Demineralized water Q.S.
EXAMPLE 7
[0039]
7 Moisturizing Cream wt % Tocopherol 2 Quercetin/Lycopene 2.5
Carbopol .TM. 0.3 Triethanolamine 0.5 Mineral Oil 1.5 Safflower oil
0.3 Squalene 1.7 Dimethicone 0.7 Allantoin 1 Oleyl alcohol 0.6
Cholesterol 4.5 Lanolin oil 0.6 Mangostin 0.001-20 Vehicle Q.S.
[0040] It should be understood that the foregoing description is
only illustrative of the present invention. Various alternatives
and modifications can be devised by those skilled in the art
without departing from the invention. Accordingly, the present
invention is intended to embrace all such alternatives,
modifications and variances which fall within the scope of the
appended claims.
* * * * *